Nation
H

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type
80638	11/AL/0309	80516	NHS Permission
80639	14/YH/1108	141368	NHS Permission
80640	15/SC/0310	167868	NHS Permission
80641	14/NW/1128	152982	NHS Permission
80642	15/NW/0626	184626	NHS Permission
80643	15/LO/1895	181595	NHS Permission
80644	15/SC/0443	173722	NHS Permission
80645	14/SC/0171	120104	NHS Permission
80646	11/SC/0528	73866	NHS Permission
80647	15/NI/0169	184948	NHS Permission
80648	12/NW/0361	103977	NHS Permission

80649	13/NW/0068	115309	NHS Permission
80650	11/SW/0160	50632	NHS Permission
80651	09/H1008/137	24269	NHS Permission
80652	13/EM/0459	137785	NHS Permission
80653	15/NI/0207	187243	NHS Permission
80654	14/YH/1259	163195	NHS Permission
80655	15/EM/0492	189756	NHS Permission
80656	14/NW/1014	141897	NHS Permission
80657	15/WA/0241	183747	NHS Permission
84976	15/EE/0464	183877	NHS Permission
85083	11/WM/0381	84585	NHS Permission
85084	13/SC/0645	143871	NHS Permission

NHS
nal Institute for
Health Research

Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?
Treatment In the Morning versus Evening	23/07/2015	13/08/2015	Yes
A randomized phase III trial comparing radical hysterectomy and pelvic node dissection versus simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer (SHAPE)	31/07/2015	31/07/2015	Yes
BOX 3 ? The Bart?s-Oxford family study of childhood diabetes: Longitudinal and multi-generational analysis of a changing disease	17/12/2015	23/12/2015	Yes
MaPLe ? Molecular profiling for lymphoma	18/11/2015	18/11/2015	Yes
A phase 3, randomised, double-blind, placebo-controlled, parallel group, multi-centre study to evaluate the net clinical benefit of Sotagliflozin as adjunct to insulin therapy in type 1 diabetes	16/12/2015	16/12/2015	Yes
Effective pre-oxygenation using high flow humidified nasal oxygen delivery system (EPOD)	23/11/2015	02/12/2015	Yes
OPTIMISE ? Long term clear skin maintenance treatment optimisation in patients with moderate to severe chronic plaque psoriasis: A randomised, multi-centre, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg s.c.	16/12/2015	16/12/2015	Yes
A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours	21/10/2015	22/10/2015	Yes
A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer	10/12/2015	11/12/2015	No
The impact of severe hypoglycaemic events requiring interventions in patients with type I diabetes patients treated insulin therapy	22/10/2015	23/10/2015	Yes
A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard and New Antiepileptic Drugs (SANAD-II)	08/10/2015	08/10/2015	Yes

Investigation of Factors Influencing Psoriatic Arthritis and Psoriasis Response to Therapy with Biologic Drugs	13/10/2015	16/10/2015	Yes
UK Multiple Sclerosis Register	08/12/2015	08/12/2015	Yes
The long-term Safety and Efficacy of Biologic Therapies in Children with Rheumatic Diseases (BSRBR-JIA)	12/01/2016	13/01/2016	Yes
POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes.	13/01/2016	13/01/2016	Yes
Toolkit to benchmark young person friendly services in rheumatology	26/02/2016	08/03/2016	Yes
Comparison of Alitretinoin with PUVA as the first line treatment in patients with severe chronic hand eczema (ALPHA)	21/03/2016	22/03/2016	No
A retrospective real world research study to describe the use of buccal midazolam maleate (Epistatus®) in adults in routine practice in the UK	18/01/2016	18/01/2016	Yes
UK CLL Biobank study	07/10/2015	16/11/2015	Yes
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two	22/03/2016	22/03/2016	Yes
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients with Catecholamine-Resistant Hypotension (CRH)	25/04/2016	27/04/2016	Yes
De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma	12/10/2015	14/10/2015	Yes
Pre-eclampsia in Hospital: Early Induction or Expectant Management	02/04/2016	02/04/2016	Yes

Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Benchmark Met	Date Study Initiated
25/08/2015	21	12	33	Yes	
14/01/2016	0	167	167	No	
15/02/2016	6	54	60	Yes	
04/01/2016	0	47	47	Yes	
26/01/2016	0	41	41	Yes	
03/12/2015	9	1	10	Yes	
27/01/2016	0	42	42	Yes	
07/01/2016	1	77	78	No	
	1				
17/11/2015	1	25	26	Yes	
16/11/2015	0	39	39	Yes	

05/11/2015	3	20	23	Yes	
05/01/2016	0	28	28	Yes	
21/03/2016	1	68	69	Yes	
21/03/2016	0	68	68	Yes	
14/03/2016	11	6	17	Yes	
	1				
02/02/2016	0	15	15	Yes	
04/03/2016	40	109	149	No	
09/05/2016	0	48	48	Yes	
23/06/2016	2	57	59	Yes	
16/05/2016	2	215	217	No	
10/06/2016	0	69	69	Yes	

Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status

Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues
				Y	
				Y	

				Y	

F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other
			Y	
	Y			
	Y			

Y				

Comments	Reasons for delay correspond to:
	Neither
	Neither
	Please Select...
	Please Select...
Awaiting sponsor providing a prescription form	Sponsor
20 patients recruited, recruitment complete	Please Select...
	Please Select...
Sponsor initiated site on 26/11/2015	Sponsor
Patient declined	Neither
	Please Select...
	Please Select...

	Please Select...
	Please Select...
	Please Select...
	Please Select...
	Please Select...
Sponsor has insisted on processing an amendment before recruitment could commence	Sponsor
	Please Select...
Sub study not available for existing patients	Sponsor
	Please Select...
	Please Select...
Awaiting QA Approval.	Sponsor
	Please Select...
	Please Select...

Errors

Warnings				